Carcinoma News and Research

RSS

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.

Study provides extensive review of incidence, risk factors and characteristics of skin cancer in people of color

While people of color have a lower risk of developing skin cancer than Caucasians, they are not immune to the disease. In fact, skin cancer is often diagnosed at a more advanced stage in people of color, which can make it more difficult to treat.

6 Feb 2014

Pfizer and Merck join forces to explore therapeutic potential of anti-PD-1 therapy

Pfizer Inc. announced today that it has agreed with Merck & Co., Inc., known as MSD outside the United States and Canada ("Merck"), through two Merck subsidiaries, to explore the therapeutic potential of Merck's investigational anti-PD-1 therapy, MK-3475, in combination with two Pfizer oncology assets.

5 Feb 2014

Findings expand treatment options for hormone-dependent breast cancer

According to the United States Centers for Disease Control and Prevention, breast cancer is the most common cancer in women. For patients whose breast cancers are hormone-dependent, current treatment focuses on using drugs that block estrogen (a type of hormone) from attaching to estrogen receptors on tumor cells to prevent the cells from growing and spreading.

5 Feb 2014

Digital mammography screening with new photon-counting technique offers high diagnostic performance

Digital mammography screening with new photon-counting technique offers high diagnostic performance, according to a study published online in the journal Radiology.

4 Feb 2014

Researchers identify potential genes that can be targeted for new treatments for hepatocellular cancer

Patients with advanced hepatocellular (or liver) cancer have high mortality rates, with existing drugs demonstrating only a small, but significant survival advantage. By combining a zebrafish model of liver cancer with data from human tumors, researchers from the Icahn School of Medicine at Mount Sinai hope to identify potential genes of interest that can be targeted for new treatments for hepatocellular carcinoma, the most common form of liver cancer to develop from liver cells.

31 Jan 2014

TCGA Research Network identify new potential therapeutic targets for major form of bladder cancer

Investigators with The Cancer Genome Atlas (TCGA) Research Network have identified new potential therapeutic targets for a major form of bladder cancer, including important genes and pathways that are disrupted in the disease.

30 Jan 2014

Patients receiving APBI after breast-conserving surgery show excellent tumor control, breast cosmesis

Long-term outcomes of breast cancer patients receiving adjuvant accelerated partial breast irradiation after breast-conserving surgery show excellent tumor control and breast cosmesis (cosmetic outcomes) with minimal late toxicity, according to a study published in the February 1, 2014 print edition of the International Journal of Radiation Oncology.

30 Jan 2014

Findings on molecular defects behind bladder cancer may pave way for new, targeted treatments

The once sketchy landscape of the molecular defects behind bladder cancer now resembles a road map to new, targeted treatments thanks to the unified efforts of scientists and physicians at 40 institutions.

30 Jan 2014

EBRT provides higher breast preservation rate in women with invasive breast cancer

Standard external beam radiation therapy (EBRT) provided a higher breast preservation rate than brachytherapy in women age 66 and older with invasive breast cancer, according to a study published in the February 1, 2014 print edition of the International Journal of Radiation Oncology ● Biology ● Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).

30 Jan 2014

Veterans with exposure to Agent Orange may be at higher risk for skin cancer

Vietnam War veterans with prior exposure to the herbicide Agent Orange may be at higher risk for certain types of skin cancer, suggests a report in the February issue of Plastic and Reconstructive Surgery-, the official medical journal of the American Society of Plastic Surgeons (ASPS).

29 Jan 2014

BioTime: OncoCyte initiates clinical development of bladder cancer diagnostic test in U.S, China

BioTime, Inc. and its subsidiary OncoCyte Corporation today announced that OncoCyte has initiated clinical development of its bladder cancer diagnostic test in both the United States and China.

28 Jan 2014

BRAF mutations rare in Japanese NSCLC patients

Research in a Japanese cohort of patients with non-small-cell lung cancer indicates that the frequency of BRAF mutations is low and their presence has limited prognostic significance.

27 Jan 2014

South Korean lung SCC genetic secrets revealed

Close examination of DNA taken from squamous cell carcinoma of the lung in South Korean patients has identified a gene fusion that may be targeted by current treatments, scientists say.

27 Jan 2014

FDA meeting streamlines pathway to initial U.S. approval of Provectus's PV-10 oncology drug

Provectus Biopharmaceuticals, Inc. (PVCT), a development-stage oncology and dermatology biopharmaceutical company, today announced that it has received the official minutes from the Type C meeting held with the FDA's Division of Oncology Products 2 on December 16, 2013.

27 Jan 2014

First patient dosed in ADXS-HPV Phase 1/2 study for HPV-associated head and neck cancer

Advaxis, Inc., a leader in developing the next generation of cancer immunotherapies, announced that the first patient has been dosed in a Phase 1/2 "window of opportunity" study being conducted by the Icahn School of Medicine at Mount Sinai. Patients diagnosed with HPV-associated head and neck cancer will receive ADXS-HPV immunotherapy during the "window" of time between initial diagnosis and minimally invasive transoral robotic surgery to remove their tumors.

21 Jan 2014

Monitoring individuals with chronic HBV is cost-effective strategy for China

A novel study determined that monitoring inactive chronic hepatitis B (HBV) carriers is a cost-effective strategy for China. However, results published in Hepatology, a journal of the American Association for the Study of Liver Diseases, show that increasing treatment, monitoring and adherence to therapy are necessary to achieve significant health benefits at the population level.

16 Jan 2014

Foundation Medicine announces discovery of high incidence of ERBB2 alterations in MPUC patients

Foundation Medicine, Inc. today announced the discovery of a high incidence of ERBB2 (HER2) extracellular domain alterations in patients with micropapillary urothelial carcinoma, a particularly aggressive form of urinary bladder cancer, using FoundationOne. The research was published in the current edition of Clinical Cancer Research.

10 Jan 2014

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has spread to other parts of the body) with BRAF V600E or V600K mutations.

9 Jan 2014

Rexahn Pharmaceuticals initiates RX-3117 Phase Ib trial in cancer patients with solid tumors

Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company, announced today the initiation of a Phase Ib clinical trial to study the safety and efficacy of RX-3117 in cancer patients with solid tumors.

9 Jan 2014

Blueprint Medicines closes $25 million Series B financing

Blueprint Medicines today announced the completion of a $25 million Series B financing. The oncology-focused investor, Nextech Invest Ltd., led the round, which also included founding investors Third Rock Ventures and Fidelity Biosciences as well as public investors Biotech Value Fund, L.P., Casdin Capital, LLC and other undisclosed investors.

7 Jan 2014

Carcinoma News and Research

Further Reading

Study provides extensive review of incidence, risk factors and characteristics of skin cancer in people of color

Pfizer and Merck join forces to explore therapeutic potential of anti-PD-1 therapy

Findings expand treatment options for hormone-dependent breast cancer

Digital mammography screening with new photon-counting technique offers high diagnostic performance

Researchers identify potential genes that can be targeted for new treatments for hepatocellular cancer

TCGA Research Network identify new potential therapeutic targets for major form of bladder cancer

Patients receiving APBI after breast-conserving surgery show excellent tumor control, breast cosmesis

Findings on molecular defects behind bladder cancer may pave way for new, targeted treatments

EBRT provides higher breast preservation rate in women with invasive breast cancer

Veterans with exposure to Agent Orange may be at higher risk for skin cancer

BioTime: OncoCyte initiates clinical development of bladder cancer diagnostic test in U.S, China

BRAF mutations rare in Japanese NSCLC patients

South Korean lung SCC genetic secrets revealed

FDA meeting streamlines pathway to initial U.S. approval of Provectus's PV-10 oncology drug

First patient dosed in ADXS-HPV Phase 1/2 study for HPV-associated head and neck cancer

Monitoring individuals with chronic HBV is cost-effective strategy for China

Foundation Medicine announces discovery of high incidence of ERBB2 alterations in MPUC patients

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

Rexahn Pharmaceuticals initiates RX-3117 Phase Ib trial in cancer patients with solid tumors

Blueprint Medicines closes $25 million Series B financing

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News